Navigation Links
TorreyPines Therapeutics, Inc. Hires Advisor to Evaluate Strategic Alternatives
Date:4/15/2009

LA JOLLA, Calif., April 15 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has hired Merriman Curhan Ford as its financial advisor to assist in the evaluation of strategic options, including the possible sale of the Company or its assets.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics, Inc. is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, and xerostomia. The company currently has three clinical stage product candidates: two ionotropic glutamate receptor antagonists and one muscarinic receptor agonist. Further information is available at www.tptxinc.com.

This press release contains forward-looking statements or predictions. Such statements are subject to numerous known and unknown risks, uncertainties and other factors, which may cause TorreyPines' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These and other risks which may cause results to differ are described in greater detail in the "Risk Factors" section of TorreyPines' annual report on Form 10-K for the year ended December 31, 2008 and TorreyPines' other SEC reports. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TorreyPines undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    Company contact:
    Craig Johnson
    Chief Financial Officer
    TorreyPines Therapeutics, Inc.
    858-623-5665 x 158
    cjohnson@TPTXinc.com



'/>"/>
SOURCE TorreyPines Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. TorreyPines NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects
2. TorreyPines Therapeutics Announces Management Change and Second Quarter 2008 Financial Results
3. TorreyPines Therapeutics Reports First Quarter 2008 Financial Results and Accomplishments
4. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
5. Gamma Secretase Modulators Show Promise in Alzheimers Disease Animal Model Efficacy Studies, According to Research Conducted by TorreyPines Therapeutics
6. TorreyPines Therapeutics to Present at BMO Capital Markets Focus on Healthcare Conference
7. TorreyPines Therapeutics to Present at the JMP Securities Healthcare Focus Conference
8. Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
9. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
10. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
11. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... An April Gallup survey found rising health ... employees of Sun Health Senior Living (SHSL) may not share those same ... and prescription copays for the year, while holding the line on increasing their contributions, ...
(Date:5/26/2016)... ... May 26, 2016 , ... Leadership of ... today announced the organization has earned its ISO 13485 certification, indicating the company’s ... with all rules and policies associated with ISO quality standard 13485. , ...
(Date:5/26/2016)... ... ... North Cypress Medical Center hosted its 9th Annual Spring Classic Golf ... of community partners, the event organizers raised $45,000 for the Lone Survivor Foundation ... their families through health, wellness, and therapeutic support. , A special military three-plane ...
(Date:5/26/2016)... ... May 26, 2016 , ... The MIAMI Institute for Age ... speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness Physician of the ... a member of the Institute for Functional Medicine. , He also heads up FITTLab, ...
(Date:5/26/2016)... CA (PRWEB) , ... May 26, 2016 , ... ... (also knowns as a bunionette) treatment was more than humbled by customer demand over ... one of their SKU's mid sale. Now that Bunion Bootie has completely replenished its ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... , May 26, 2016 ... Associated With Both Cost Savings and Overall ... plc (LSE: BTG), an international specialist healthcare company, ... at the 21st Annual Meeting of ISPOR (International ... treatment of hepatocellular carcinoma (HCC) using yttrium-90 glass ...
(Date:5/25/2016)... , May 25,2016 ... the near-infrared Cellvizio platform for urological and surgical ... OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal ... regulatory milestone in the US with the 12 ... and Drug Administration (FDA). This new FDA clearance ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: